본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Regional disparities in the availability of cancer clinical trials in Korea

이용수 2

영문명
Regional disparities in the availability of cancer clinical trials in Korea
발행기관
한국역학회
저자명
Jieun Jang Wonyoung Choi Sung Hoon Sim Sokbom Kang
간행물 정보
『Epidemiology and Health』46, 1~8쪽, 전체 8쪽
주제분류
의약학 > 면역학
파일형태
PDF
발행일자
2024.01.31
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

OBJECTIVES: Unequal access to cancer clinical trials is an important issue, given the potential benefits of participation for cancer patients. We evaluated regional disparities in access to cancer clinical trials in Korea. METHODS: From the Ministry of Food and Drug Safety database, we extracted 2,465 records of all cancer clinical trials approved between January 2012 and April 2023. To measure disparities in cancer clinical trial access, we calculated the ratio of clinical trials open to non-capital areas relative to those open to capital areas. We then analyzed temporal trends in this ratio, which we termed the trial geographical equity index (TGEI). RESULTS: Disparities in access to cancer clinical trials, as indicated by the TGEI, did not significantly improve during the study period (regression coefficient, 0.002; p=0.59). However, for phase II/III trials sponsored by global pharmaceutical companies, the TGEI improved significantly (regression coefficient, 0.021; p<0.01). In contrast, the TGEI deteriorated for trials initiated by investigators or those testing domestically developed therapeutics (regression coefficient, -0.015; p=0.05). Furthermore, the increasing trend of TGEI for phase II/III trials sponsored by global companies began to reverse after 2019, coinciding with the outbreak of coronavirus disease 2019 (COVID-19). CONCLUSIONS: Over the past decade, access to cancer clinical trials has improved in Korea, particularly for phase II/III trials evaluating therapeutics from global companies. However, this increase in accessibility has not extended to trials initiated by investigators or those assessing domestically developed therapeutics. Additionally, the impact of COVID-19 on disparities in clinical trial access should be closely monitored.

목차

INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

Jieun Jang,Wonyoung Choi,Sung Hoon Sim,Sokbom Kang. (2024).Regional disparities in the availability of cancer clinical trials in Korea. Epidemiology and Health, (), 1-8

MLA

Jieun Jang,Wonyoung Choi,Sung Hoon Sim,Sokbom Kang. "Regional disparities in the availability of cancer clinical trials in Korea." Epidemiology and Health, (2024): 1-8

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제